Skip to main content
impaact logo Return to homepage
  • Contact
    • Directory
  • About
    • Mission
    • Network Structure
      • Leadership
    • Areas of Research
      • Cure & Immunotherapy
      • Brain & Mental Health
      • Therapeutics
      • Tuberculosis
      • Social Behavioral Scientific Core (SBSC)
    • Early Career Investigator Program
    • Staff Spotlights
    • Funding Acknowledgements
    • Network Sites
      • Study Site Map
  • Studies
    • Research and Study Opportunities
    • Submit a Research Proposal
    • IMPAACT Study Snapshots
  • Community Engagement
    • ICAB Leadership Group
    • IMPAACT Community Advisory Board (ICAB)
    • Operations Center Staff
    • Resources
      • Acronyms
    • Site Community Advisory Boards
    • Community Meetings and Webinars
  • News & Events
    • Events and Conferences
    • IMPAACT Annual Meeting
    • Newsletters
    • Past Conference Presentations
    • Spotlight Series
  • Resources
    • COVID-19 Resources
    • HIV/AIDS Network Coordination (HANC)
    • Lab Center
      • Laboratory Committees
      • Laboratory Guidance Documents
      • Laboratory Resources for Quality Management
      • MiLab Resources
      • Specimen Repository
    • Manual of Procedures
    • Media Release Form
    • Network Logos & Templates
    • Regulatory Resources
    • Training Opportunities
    • NIH Updates
  • Publications
    • Abstracts
    • Manuscripts
  • Enter a search term.
Back to Directory

Scott Watson

Email

scottwatson@westat.com

Phone

(415) 494-5575

Institution

Westat Inc.

Title

Address

Westat Inc.
1441 W. Montgomery Ave.
Rockville, MD 20850
United States of America
Request an Update

Affiliated Studies

IMPAACT 2017: MOCHA

DAIDS Number

30070

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

P1052: Abacavir PK Study in HIV-1 Infected Adolescents and Young Adults

DAIDS Number

10194

Research Area

Other

Study Status

Concluded

P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study

DAIDS Number

11954

Research Area

Cure and Immunotherapy

Study Status

Enrolling

P1059: Phase I Trial of Recombinant Vaccines in HIV+ Young Adults

DAIDS Number

10051

Research Area

Other

Study Status

Concluded

IMPAACT 2011: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID delta M2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

30072

Research Area

Complications & Comorbidities

Study Status

Concluded
Show All
IMPAACT logo Return to homepage

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.

Stay connected with the IMPAACT Network

Follow IMPAACT

Sign up for our newsletter

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Sitemap Privacy Notice

© 2020 IMPAACT Network